Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 17/20 | 0.78 |
| ▸ | FTO | Q9C0B1 | 7/20 | 0.53 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.53 |
| ▸ | THRA | P10827 | 3/20 | 0.51 |
| ▸ | THRB | P10828 | 3/20 | 0.51 |
| ▸ | KDM6B | O15054 | 2/20 | 0.45 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.44 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | ASPH | Q12797 | 1/20 | 0.41 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.41 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | PTPRF | P10586 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPRA | P18433 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1270309 | 0.89 | EGLN1 (0.61) | EGLN1 | |
| SCHEMBL1269861 | 0.88 | EGLN1 (0.60) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL1270241 | 0.88 | EGLN1 (0.60) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL1269131 | 0.87 | EGLN1 (1.00) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL1270342 | 0.86 | EGLN1 (1.00) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL1270123 | 0.84 | EGLN1 (0.55) | EGLN1PTPN1 | |
| SCHEMBL1269306 | 0.84 | EGLN1 (1.00) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL3623430 | 0.83 | EGLN1 (0.52) | EGLN1PTPRCPTPRFPTPN1PTPRA | |
| SCHEMBL1269585 | 0.83 | EGLN1 (0.54) | EGLN1 | |
| SCHEMBL1269290 | 0.81 | EGLN1 (0.53) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028507-A1 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | CRYSTALGENOMICS, INC. (KR) | 2011-02-03 | — | — | US | claimed |
| CN-101815718-A | Pyridine derivate and using method thereof | CRYSTALGENOMICS INC | 2010-08-25 | — | — | CN | claimed |
| EP-2188295-A2 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | Crystalgenomics, Inc. (KR) | 2010-05-26 | — | — | EP | claimed |
| WO-2009037570-A2 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | CRYSTALGENOMICS, INC. (KR) | 2009-03-26 | — | — | WO | claimed |
| US-20110028507-A1 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | CRYSTALGENOMICS, INC. (KR) | 2011-02-03 | — | — | US | disclosed |
| CN-101815718-A | Pyridine derivate and using method thereof | CRYSTALGENOMICS INC | 2010-08-25 | — | — | CN | disclosed |
| EP-2188295-A2 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | Crystalgenomics, Inc. (KR) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009037570-A2 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | CRYSTALGENOMICS, INC. (KR) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028507-A1 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | EGLN3, EGLN2, HIF1A | EGLN1 5/4885FTO 1284/4885BBOX1 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.